Alzamend begins phase 2 trial for lithium-based oral treatment for Alzheimer’s disease

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Alzamend Neuro Inc. has announced the launch of a phase 2A trial for its AL001 treatment for mild to moderate Alzheimer’s dementia.

AL001 is being developed as an oral lithium-based therapy and has the potential to deliver lithium carbonate to the brain while mitigating or avoiding current toxicities associated with lithium.

Source: Adobe Stock.

“Advancing AL001 into a phase 2A clinical trial as planned marks an important milestone for Alzamend,” Alzamend CEO Stephan Jackman said in a released statement. “We are one step closer to proving that AL001 could potentially provide clinicians with a major improvement over current lithium-based treatments and may constitute a means of treating over 40 million Americans suffering from Alzheimer’s and other neurodegenerative diseases and psychiatric disorders.”

The first patient with mild to moderate AD has received a dose of AL001 in a 12-month multiple ascending dose (MAD) study, which will evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions and determine the maximum tolerated dose in patients diagnosed with AD.

According to the release, lithium has been well-characterized for safety and is currently approved in multiple formulations for the treatment of bipolar affective disorders. Dosing for the MAD study is based on a fraction of the typical lithium dose used in these treatments.

“We look forward to completing the MAD study and further advancing clinical development of this promising potential therapeutic,” Jackman said.

Leave a Reply

Your email address will not be published.